Boron
US-FDASourced from openFDA
GET
/api/v1/drug/boronFAERS reports
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
0 total reports matchedShare = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
- 1Headache36—
- 2Fatigue28—
- 3Pain25—
- 4Arthralgia19—
- 5Nausea18—
- 6Diarrhoea17—
- 7Dizziness17—
- 8Feeling Abnormal15—
- 9Drug Ineffective14—
- 10Muscle Spasms14—
- 11Nasopharyngitis14—
- 12Gait Disturbance13—
- 13Peripheral Swelling13—
- 14Urinary Tract Infection13—
- 15Anxiety12—
Literature
Recent PubMed references pinned to Boron as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.
- Physiological homeostasis, yield, and sugar profile of salt-stressed sugar beet plants as influenced by nano-structured mixture of zinc, boron, and molybdenum application.Scientific reports · 2026 · El-Nasr EKA, Rizk TY, Saudy HS, et al.PMID 42243398DOI 10.1038/s41598-026-54565-2
- Evaluation of neutron and gamma shielding performance of borated polyethylene using PHITS/MCNP Monte Carlo simulations and experimental measurements.Journal of radiological protection : official journal of the Society for Radiological Protection · 2026 · Kumar Meena R, Meena D, Kumar Gupta S, et al.PMID 42202834DOI 10.1088/1361-6498/ae7385
- Label-Free Electrochemiluminescence Detection of Urinary AD7c-NTP Using Structurally Optimized Iridium(III) Complexes on Boron-Doped Diamond Electrodes.Analytical chemistry · 2026 · Wang T, Zhou Y, Wang B, et al.PMID 42126049DOI 10.1021/acs.analchem.6c00503
- Effects of boron and nitrogen doping on the electronic properties of graphene-based heterostructures with two-dimensional semiconducting materials.PloS one · 2026 · Liu Z, Huang P, Luo Y, et al.PMID 42102163DOI 10.1371/journal.pone.0348086
- Design, Synthesis, and Biological Activity of Boron-Bearing Sugar Derivatives for Boron Neutron Capture Therapy (BNCT).Molecules (Basel, Switzerland) · 2026 · Hou M, Li X, Li Y, et al.PMID 42075910DOI 10.3390/molecules31081230
- A novel boron-doped NiCo-LDH catalyst: Rapid activation of peroxymonosulfate for efficient tetracycline degradation.Journal of environmental sciences (China) · 2026 · Zuo Y, Yang Z, Zhang P, et al.PMID 42070840DOI 10.1016/j.jes.2025.07.027
- Application of the prompt γ-ray spectroscopy in the boron neutron capture therapy of pets.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine · 2026 · Maltseva VD, Bykov TA, Chesnokova YL, et al.PMID 42054749DOI 10.1016/j.apradiso.2026.112648
- Design, Synthesis, and Evaluation of an Ammonium-Terminated Superchaotropic Boron Cluster: Effects on the Transmembrane Delivery of Neutral and Charged Cargos.Inorganic chemistry · 2026 · Nakajima R, Yamamoto S, Kawamura YK, et al.PMID 42042618DOI 10.1021/acs.inorgchem.5c05467
Clinical trials
The 10 most recently updated of 977 ClinicalTrials.gov registrations naming Boron as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple MyelomaActive not recruiting · Phase 3 · Interventional · 21 enrolled · GlaxoSmithKlineNCT06956170updated 2026-06-12
- Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple MyelomaActive not recruiting · Phase 3 · Interventional · 302 enrolled · GlaxoSmithKlineNCT04484623updated 2026-06-12
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaRecruiting · Phase 3 · Interventional · 380 enrolled · AbbVieNCT06158841updated 2026-06-12
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple MyelomaActive not recruiting · Phase 3 · Interventional · 525 enrolled · National Cancer Institute (NCI)NCT00644228updated 2026-06-11
- A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)Recruiting · Phase 3 · Interventional · 508 enrolled · AstraZenecaNCT07391657updated 2026-06-11
- A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)Recruiting · Phase 2 · Interventional · 200 enrolled · GlaxoSmithKlineNCT07227311updated 2026-06-10
- Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable TreatmentRecruiting · Phase 3 · Interventional · 510 enrolled · SWOG Cancer Research NetworkNCT05561387updated 2026-06-10
- A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Recruiting · Phase 3 · Interventional · 810 enrolled · CelgeneNCT05519085updated 2026-06-10
- Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple MyelomaNot yet recruiting · Observational · 100 enrolled · PETHEMA FoundationNCT07637526updated 2026-06-09
- Acalabrutinib Maleate and Bortezomib for Patients With HLA AntibodiesNot yet recruiting · Phase 3 · Interventional · 42 enrolled · The First Affiliated Hospital of Soochow UniversityNCT07635511updated 2026-06-09
Frequently asked questions
- What are the brand names for Boron?
- Boron is marketed under brand names including Folgard OS.
Note. Data for
boron is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.